Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lucio Luzzatto

Showing results (131-140 of 140) with videos related to

Pageof 14
Sort By:
You have reached the last page of results.This site can display upto 140 results.
Blood|August 19, 2007
Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuriaPeter Hillmen, Petra Muus, Ulrich Dührsen, et al.
British Journal of Haematology|September 19, 2024
Pathogenic G6PD variants: Different clinical pictures arise from different missense mutations in the same codonSimonetta Costa, Angelo Minucci, Amit Kumawat, et al.
The American Journal of Tropical Medicine and Hygiene|July 28, 2017
Hemolytic Potential of Tafenoquine in Female Volunteers Heterozygous for Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency (<i>G6PD Mahidol</i> Variant) versus G6PD-Normal VolunteersRonnatrai Rueangweerayut, Germana Bancone, Emma J Harrell, et al.
Oncology Research|March 1, 2008
Analysis of gene expression profiles reveals novel correlations with the clinical course of colorectal cancerDuccio Cavalieri, Piero Dolara, Enrico Mini, et al.
The Lancet. Haematology|February 1, 2020
SickleInAfricaJulie Makani, Raphael Z Sangeda, Obiageli Nnodu, et al.
Blood|January 31, 2009
Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumabAntonio M Risitano, Rosario Notaro, Ludovica Marando, et al.
BMC Hematology|November 22, 2018
A ten year review of the sickle cell program in Muhimbili National Hospital, TanzaniaJulie Makani, Furahini Tluway, Abel Makubi, et al.
The New England Journal of Medicine|September 23, 2006
The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuriaPeter Hillmen, Neal S Young, Jörg Schubert, et al.
Nature Genetics|October 2, 2019
Germline NPM1 mutations lead to altered rRNA 2'-O-methylation and cause dyskeratosis congenitaDaphna Nachmani, Anne H Bothmer, Silvia Grisendi, et al.
ESMO Open|August 30, 2017
The European Cancer Patient's Bill of Rights, update and implementation 2016Mark Lawler, Ian Banks, Kate Law, et al.
Pageof 14

Showing results (131-140 of 140) with videos related to

Sort By:
Pageof 14
You have reached the last page of results.This site can display upto 140 results.
Blood|August 19, 2007
Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuriaPeter Hillmen, Petra Muus, Ulrich Dührsen, et al.
British Journal of Haematology|September 19, 2024
Pathogenic G6PD variants: Different clinical pictures arise from different missense mutations in the same codonSimonetta Costa, Angelo Minucci, Amit Kumawat, et al.
The American Journal of Tropical Medicine and Hygiene|July 28, 2017
Hemolytic Potential of Tafenoquine in Female Volunteers Heterozygous for Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency (<i>G6PD Mahidol</i> Variant) versus G6PD-Normal VolunteersRonnatrai Rueangweerayut, Germana Bancone, Emma J Harrell, et al.
Oncology Research|March 1, 2008
Analysis of gene expression profiles reveals novel correlations with the clinical course of colorectal cancerDuccio Cavalieri, Piero Dolara, Enrico Mini, et al.
The Lancet. Haematology|February 1, 2020
SickleInAfricaJulie Makani, Raphael Z Sangeda, Obiageli Nnodu, et al.
Blood|January 31, 2009
Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumabAntonio M Risitano, Rosario Notaro, Ludovica Marando, et al.
BMC Hematology|November 22, 2018
A ten year review of the sickle cell program in Muhimbili National Hospital, TanzaniaJulie Makani, Furahini Tluway, Abel Makubi, et al.
The New England Journal of Medicine|September 23, 2006
The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuriaPeter Hillmen, Neal S Young, Jörg Schubert, et al.
Nature Genetics|October 2, 2019
Germline NPM1 mutations lead to altered rRNA 2'-O-methylation and cause dyskeratosis congenitaDaphna Nachmani, Anne H Bothmer, Silvia Grisendi, et al.
ESMO Open|August 30, 2017
The European Cancer Patient's Bill of Rights, update and implementation 2016Mark Lawler, Ian Banks, Kate Law, et al.
Pageof 14